CHILDREN'S HOSPITAL MEDICAL CENTER Patent applications |
Patent application number | Title | Published |
20160128690 | GASTRIC TRACTION DEVICE AND METHOD - A surgical clamp or gastric traction device and method for grasping and manipulating the stomach and providing continuous and uniform tension along a predetermined staple line during the serial stapling and stomach transection portions of a laparoscopic gastric sleeve procedure. The clamp typically includes a handle for gripping and manipulating the clamp and the engaged stomach, and a pair of elongated jaws coupled to the handle via a central portion. The pair of elongated jaws include a first jaw member and a second jaw member, and the length of the jaws are substantially equal to the length of a predetermined staple line which spans the stomach from the pyloric area to the area of the Angle of His. In one embodiment, the handle assembly can impart articulating and pivoting motion to the clamp assembly. | 05-12-2016 |
20160120720 | PATIENT SUPPORT COUPLED MEDICAL ACCESSORY SUPPORT - A medical accessory support including a coupler for coupling to a patient support, a horizontal arm pivotally connected to the coupler through a locking hinge, and a vertical post supported by an adjustment mechanism providing for both a coarse adjustment and a fine adjustment. | 05-05-2016 |
20160033596 | Detector Grid Arrays for MR Imaging - The present disclosure describes examples of magnetic resonance (MR) detector that may replace conventional MR imaging coil arrays. The present disclosure generally describes an example coil design approach that may reduce the number of components for MR imaging devices and may eliminate the need of tissue matching. In some examples, this approach implements a non-resonant grid in which MR-induced currents are allowed to flow unconstrained over the grid (unlike conventional phased array coils in which current is constrained to flow within each loop). Current in each element of the grid may be detected with inductively-coupled pickup loops, which may be attached to independent receiver channels of the MR imaging system. In one example, individual integrated balun pickup coils may be inductively coupled to each grid element. Other connection arrangements, however, may be employed if desired. | 02-04-2016 |
20150353912 | METHODS FOR TREATING AND PREVENTING RADIATION INJURY USING ACTIVATED PROTEIN C POLYPEPTIDES - Methods of treating and preventing radiation injury are provided by the present invention. In particular, provided herein are methods comprising administering to a subject an Activated Protein C (APC), Plasma Zymogen Protein C (PC), or a variant thereof to treat or prevent radiation injury and to reduce chemical toxicity in subjects receiving myelosuppressive therapy. | 12-10-2015 |
20150315611 | OPTIMIZATION OF DETERMINANTS FOR SUCCESSFUL GENETIC CORRECTION OF DISEASES, MEDIATED BY HEMATOPOIETIC STEM CELLS - Methods and compositions disclosed herein generally relates to methods of determining minimum hematopoietic stem cell (HSC) chimerism and gene dosage for correction of a hematopoietic disease; in particular, in in vivo models. The invention also relates to modified lentiviral expression vectors for increase a viral titer and various methods for increasing such titers as well as expression vectors capable of enhancing such titers. The invention also relates to CHS4 chromatin insulator-derived functional insulator sequences. The invention further relates to methods for genetic correction of diseases or reducing symptoms thereof, such as sickle cell anemia, a lysosomal storage disease. The invention further relates to a method of improving and/or correcting one or more central nervous system (CNS) abnormalities caused by one or more lysosomal storage disease. The invention further relates to methods of improving titer in transfection-based bioreactor culture production or transfection-based production systems using eukaryotic cells. | 11-05-2015 |
20150306120 | INHIBITING INFLAMMATION WITH MILK OLIGOSACCHARIDES - A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides. | 10-29-2015 |
20150241529 | Loop Coil with Integrated Balun for MR Applications - An MR loop coil design incorporates a balun into the loop coil. With this approach, some components of the coil may be simultaneously part of the imaging coil and the balun. Further, with this approach the number of components used to build an MR coil may be reduced, which may result in a reduction in cost, weight and size. This MR loop coil design may also be used to build phased array coils from the smaller loop size. Such an approach may use small feeder circuit boards oriented generally perpendicular to the coil elements to reduce interactions between the feeder boards and the coils. Such feeder boards may also be made smaller than conventional feeder circuits because the integrated balun coil design may reduce the number of components needed to create balanced coils in the array. | 08-27-2015 |
20150233942 | Use of Interleukin-27 as a Diagnostic Biomarker for Bacterial Infection in Critically Ill Patients - Embodiments of the invention are directed to methods of diagnosing bacterial infection in a critically ill patient. The methods include obtaining a sample from the patient and determining the patient's level of IL-27 expression. Embodiments of the invention are also directed to methods that include determining both the patient's levels of IL-27 expression and PCT expression and using the combined result to provide a diagnosis of bacterial infection in a critically ill patient. | 08-20-2015 |
20150102813 | Acoustic Noise Reducing RF Coil For Magnetic Resonance Imaging - An RF coil assembly for use in a Magnetic Resonance Imaging scanner incorporates sound absorbing material in its construction for the purpose of attenuating the sound perceived by a patient lying inside the RF coil. Unlike a conventional RF coil assembly in which rigid components are used to support the coil within the magnet bore, the quiet RF coil assembly is constructed without rigid support components. In one embodiment, open cell foam may be used to support the RF coil components and the entire assembly is wrapped in a. flexible cloth-like material. | 04-16-2015 |
20150079055 | USE OF SECRETOR, LEWIS AND SIALYL ANTIGEN LEVELS IN CLINICAL SAMPLES AS PREDICTORS OF RISK FOR DISEASE - An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewis | 03-19-2015 |
20150050284 | ANTIBODY BINDING MICROBIAL HEPARIN BINDING MOTIF TO RETARD OR PREVENT MICROBIAL BIOFILM FORMATION ON IMPLANTED MEDICAL DEVICES - Methods and reagents for ameliorating biofilm formation on a surface of an indwelling or implanted device in a patient resulting in decreased virulence of microorganisms such as | 02-19-2015 |
20150038570 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 02-05-2015 |
20150025067 | USE OF SMALL MOLECULE INHIBITORS TARGETING THE INTERACTION BETWEEN RAC GTPASE AND P67 (PHOX) - Inhibitors of p67 | 01-22-2015 |
20150018326 | COMPOSITIONS AND METHODS FOR INHIBITING NOROVIRUS INFECTION - A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia is disclosed. The composition may contain a therapeutically effective amount of a binding-inhibiting compound and a carrier and/or excipient. The compounds may competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions may be administered to a human prior to or after infection by a Norovirus, to prevent, ameliorate, or reduce the effects of an infection. | 01-15-2015 |
20140376794 | Correlation Imaging For Multi-Scan MRI With Multi-Channel Data Acquisition - A framework is provided for accelerating multi-scan and multi-channel data acquisition in a clinical MRI protocol by estimating correlation functions from images previously acquired or reconstructed, with the same or with different contrast and resolution. Using an MRI apparatus, the method collects a plurality of prior MRI image scan data sets, obtains a current MRI scan data, and reconstructs the current MRI scan data set using an aggregate of the plurality of prior MRI image data sets. The method provided may optimize previously acquired MRI image data sets to reconstruct an MRI image scan data set and image. | 12-25-2014 |
20140364722 | MRI Transfer Table Assembly - The present disclosure relates to a transfer table assembly suitable for use in association with an MR scanner. The transfer table assembly includes a transfer table attached to a transfer table base that may releasably engage an incubator. The transfer table may be dimensionally constructed such that it may be inserted directly into an MR scanner. | 12-11-2014 |
20140357981 | MRI Transfer Station and Dock - A patient table adapted for use in association with an MR scanner for neonatal infants is provided. The patient table has an extendable patient bed attached to and extendable from the patient table. The patient bed may be at least partially inserted into an MR scanner without requiring the patient table to enter the MR scanner. A transport mechanism is on the underside of the patient table so that it may be readily moved over the floor on which it rests. The patient table includes a latching mechanism that may operate to releasably attach the patient table to a patient table docking assembly. The docking assembly is operative to selectively move the patient table towards, into and away from the MR scanner. | 12-04-2014 |
20140354279 | Faraday Cage For MR Imaging With Accessory Equipment - A Faraday cage assembly for use with a Magnetic Resonance (MR) Imaging scanner is deployed inside the MR scanner room. The Faraday cage assembly is configured to accept accessory medical equipment which is desired to be attached to the patient during scanning. Accessory medical equipment can include patient monitoring systems, injector pumps, and intravenous (IV) poles with infusion pumps. Once the accessory medical equipment is placed inside the Faraday cage, radiofrequency (RF) interference emitted by the accessory medical equipment is contained within the cage and cannot significantly degrade MR image quality. The cage may permit non-MR compatible accessory equipment such as infusion pumps to be used without modification or reconfiguration during MR scanning. | 12-04-2014 |
20140286896 | MOLECULAR DIAGNOSTIC PANEL OF EOSINOPHILIC GASTROINTESTINAL DISORDERS - Embodiments of the invention are directed to methods of diagnosing eosinophilic gastritis (EG), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EG, analyzing the results thereof, and making a determination as to the EG status of the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EG in a subject. Embodiments of the invention are also directed to use of CDH26 as a marker for EG, eosinophilic esophagitis, or allergic inflammatory conditions. Embodiments of the invention also relate to the use of anti-CDH26-based therapeutics to treat allergic inflammatory conditions. | 09-25-2014 |
20140235687 | METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM - Methods for treating cognitive dysfunction by modulating brain energy metabolism using cyclocreatine or a pharmaceutically acceptable salt thereof are discussed. | 08-21-2014 |
20140234288 | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases - The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome. | 08-21-2014 |
20140221279 | REGULATION OF ENERGY METABOLISM AND OBESITY BY MODULATING A PROLIFERATION-INDUCING LIGAND (APRIL) OR APRIL SIGNALING - Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors. | 08-07-2014 |
20140219974 | TARGETED DELIVERY OF PROTEINS ACROSS THE BLOOD-BRAIN BARRIER - Embodiments of the invention are directed to compositions comprising a peptide sequence, or a nucleic acid encoding the same, wherein the peptide sequence includes a receptor-binding region of apolipoprotein E (apoE), or a sequence variant or fragment thereof, for directing delivery of a given protein or therapeutic across the blood brain barrier. Embodiments of the invention are also directed to methods of using the compositions for treating or preventing a neurological disorder, disease, or symptom in a subject in need thereof. | 08-07-2014 |
20140187998 | DEVICES AND TREATMENT METHODS FOR VASCULAR EYE DISEASES - A method of treating ROP, the method comprising providing a light source emitting light with a wavelength of about 490 nra, exposing an infant's eye to the light, and monitoring the vascularization in the infant's eye. | 07-03-2014 |
20140170107 | REGULATION OF ENERGY METABOLISM AND OBESITY BY MODULATING B CELL ACTIVATING FACTOR (BAFF, BLYS) OR BAFF SIGNALING - Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors. | 06-19-2014 |
20140140970 | Use of Secretor, Lewis and Sialyl Antigen Levels in Clinical Samples as Predictors of Risk for Disease - An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewis | 05-22-2014 |
20140135268 | SURFACTANT PROTEIN D FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH LUNG INJURY - Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD). | 05-15-2014 |
20140128460 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE - Inhibitors of EYA tyrosine phosphatase are provided herein, as well as pharmaceutical compositions and methods relating thereto. | 05-08-2014 |
20140107698 | GASTRIC TRACTION DEVICE AND METHOD - A surgical clamp or gastric traction device and method for grasping and manipulating the stomach and providing continuous and uniform tension along a predetermined staple line during the serial stapling and stomach transection portions of a laparoscopic gastric sleeve procedure. The clamp typically includes a handle for gripping and manipulating the clamp and the engaged stomach, and a pair of elongated jaws coupled to the handle via a central portion. The pair of elongated jaws include a first jaw member and a second jaw member, and the length of the jaws are substantially equal to the length of a predetermined staple line which spans the stomach from the pyloric area to the area of the Angle of His. In one embodiment, the handle assembly can impart articulating and pivoting motion to the clamp assembly. | 04-17-2014 |
20140087397 | BIOMARKERS FOR FANCONI ANEMIA - A method for adjusting therapy given to a patient having cancer by diagnosing Fanconi Anemia (FA), and/or predicting bone marrow failure (BMF) or predicting cancer susceptibility in the patient by determining a level of at least one biomarker. In one embodiment the biomarker is at least one of 3-hydroxyisovalerate, acetate, isopropanol, glycerol-3-phosphocholine, choline, histamine, glutamate, alanine, glycine, isoleucine, lysine, phenylalanine, threonine, tyrosine, vitamin A, vitamin D, cholesterol, ketone bodies, acetone, and/or acetoacetate/acetoacetaldehyde. The biomarker level is assessed in a biological sample obtained from the patient, and an altered level of the biomarker, increased or decreased, compared to a family member not having FA or to a healthy control subject, is indicative of FA and/or predictive of BMF and cancer susceptibility. The information is used to adjust the patient's therapy based on the diagnosis of FA and/or prediction of BMF and cancer susceptibility in the patient. | 03-27-2014 |
20140087357 | Organ Transplant Solutions and Methods for Transplanting Organs - A preservation solution for organs waiting to be transplanted is disclosed; the method of using the solution in a transplantation procedure is also disclosed. The preservation solutions comprise a balanced isotonic aqueous solution comprising sodium, potassium, calcium, magnesium and bicarbonate ions in a physiologically acceptable amount, together with an effective amount of a mutein of the C5a anaphylatoxin which is a C5a receptor antagonist wherein the amino acid residue naturally occurring at sequence position 69 is mutated. | 03-27-2014 |
20140086845 | METHOD FOR IMAGING A SITE OF ARTHRITIS IN AN ANIMAL - The present disclosure demonstrates that a nanovesicle comprising a membrane-associated lysosomal protein (saposin C; “SapC”) incorporated into a phospholipid has a high fusogenic affinity for phosphatidylserine-rich domains on the surfaces of target cell membranes. It is believed that the nanovesicles target surface exposed phosphatidylserine on the membranes of cells associated with arthritis, allowing for detection of local tissue damage associated with arthritis. In plasma membranes, phosphatidylserine is normally present only on the inner leaflet but is “flipped” to the outer leaflet upon the presence of cell damage. Incorporation of the fluorophore in the nanovesicles allows for the in vivo visualization of the fluorophore in targeted tissue and provides a technique to detect and evaluate the onset and progression of arthritic disease in an animal. Furthermore, the use of the nanovesicle in optical imaging methods provides great promise for analyzing events occurring early in the pathogenesis of arthritis and arthritic disease. | 03-27-2014 |
20140080166 | Method for the Early Detection of Renal Disease Using Proteomics - A method for the detection of an early biomarker for assessing a change in renal status in a mammalian subject following a renal event. The method typically includes the steps of (a) providing a body fluid sample obtained from a mammalian subject; (b) analyzing the molecular weight of the proteins in the sample using proteome analysis; and (c) identifying the presence of a protein in the sample selected from the group consisting of a 6.4 kDa protein, a 28.5 kDa protein, a 33 kDa protein, a 44 kDa protein, a 67 kDa protein, and combinations thereof. The presence of one of these proteins can serve as an early biomarker for assessing a change in renal status. The levels of these proteins can be compared to predetermined levels, and thus provide a determination of the subject's renal status. The invention also includes a method of assessing the administration of aprotinin during cardio-pulmonary bypass surgery and provides for methods where the level of the 6.4 kDa biomarker in the subject's urine directs a caregiver's therapeutic decision regarding the intra-operative administration of aprotinin. | 03-20-2014 |
20140039046 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 02-06-2014 |
20140031356 | THERAPY FOR LEUKEMIA - A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of BCR-ABL tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for leukemia. | 01-30-2014 |
20140018252 | GENE ARRAY TECHNIQUE FOR PREDICTING RESPONSE IN INFLAMMATORY BOWEL DISEASES - Disclosed are methods for classifying individuals having or suspected of having an inflammatory bowel disease, such as Crohn's Disease or Ulcerative Colitis, as ‘responders’ or ‘non-responders’ to first-line treatment, generally comprising the steps of a) obtaining a biological sample from the individual, b) isolating mRNA from the biological sample c) determining a gene expression profile from the biological sample; and d) comparing the gene expression profile of the individual to a reference gene expression profile or other suitable control such that changes in expression can be used to stratify individuals and predict efficacy of first-line therapy. A gene expression system is further provided for carrying out these methods. | 01-16-2014 |
20130345268 | Methods and Compositions for the Treatment of RAS Associated Disorders - The instant disclosure relates to compositions that may be useful as therapeutic agents for the treatment of disorders associated or caused by Ras deregulation or dysregulation, for example, disorders associated with alterations in the NF1 gene such as neurofibromatosis type I, fungal infections such as those caused by | 12-26-2013 |
20130324435 | ESOPHAGEAL CYTOKINE EXPRESSION PROFILES IN EOSINOPHILIC ESOPHAGITIS - Methods and compositions disclosed herein generally relate to methods of providing or enhancing a diagnosis of eosinophilic esophagitis (EE). In particular, the invention relates to obtaining a sample from a patient having at least one indication of EE, then quantifying from the sample an amount of one or more cytokines associated with EE or an mRNA corresponding to the cytokine or its receptor, wherein an altered level of the cytokine or mRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more cytokines associated with EE or an mRNA corresponding to the cytokine or its receptor. | 12-05-2013 |
20130202553 | MOBILIZATION OF HEMATOPOIETIC STEM CELLS - Methods, processes, uses, and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells and/or cancer stem cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as a Cdc-42 specific inhibitor alone or in combination with one or more additional agents. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve specific inhibition of the Cdc42 GTPase to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject. | 08-08-2013 |
20130137130 | METHODS AND SYSTEMS FOR CONVERTING PRECURSOR CELLS INTO INTESTINAL TISSUES THROUGH DIRECTED DIFFERENTIATION - The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal al development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease. | 05-30-2013 |
20130116450 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES - A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained. | 05-09-2013 |
20120283117 | DETERMINATION OF EOSINOPHILIC ESOPHAGITIS - Eosinophilic esophagitis (EE), an emerging disorder with poorly understood pathogenesis, was examined. Esophageal tissue was analyzed by a genome wide microarray expression analysis. EE patients had a transcript signature involving 1% of the genome that was conserved across gender, age, and atopic status, and was distinct from that associated with chronic esophagitis (CE). The eosinophil specific chemokine eotaxin-3 was the top induced gene compared with normal controls. Levels C of eotaxin-3 mRNA and protein correlated with disease severity. A single nucleotide polymorphism in the human eotaxin-3 gene conferred susceptibility to disease. Mice deficient in the eotaxin-3 receptor (CCR-3) were protected from experimental EE. Eotaxin-3 was identified as a specific effector molecule, biomarker, and genetic risk factor for EE, and distinguished EE from CE. | 11-08-2012 |
20120264821 | USE OF EQUOL FOR TREATING ANDROGEN MEDIATED DISEASES - Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes. | 10-18-2012 |
20120264680 | REGULATION OF ENERGY METABOLISM AND OBESITY BY MODULATING B CELL ACTIVATING FACTOR (BAFF, BLYS) OR BAFF SIGNALING - Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors. | 10-18-2012 |
20120245211 | Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism - Methods for treating cognitive dysfunction by modulating brain energy metabolism are discussed. | 09-27-2012 |
20120122967 | COMPOSITIONS AND PRODUCTS CONTAINING R-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering R-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The R-equol enantiomer can be produced by chiral-phase column separation from a racemic mixture of equol. | 05-17-2012 |
20120020878 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS - The present invention comprises a method for delivering pharmaceutical and/or imaging agents within and/or through the dermal, mucosal and other cellular membranes, and across the blood-brain barrier, utilizing a fusogenic protein. The fusogenic protein is associated with a phospholipid membrane, such as a liposome. The liposome may include dioleoylphosphatidylserine, a negatively charged long-chain lipid. Alternatively, the liposome is comprised of a mixture of negatively charged long-chain lipids, neutral long-chain lipids, and neutral short-chain lipids. Preferred fusogenic proteins include saposin C and other proteins, polypeptides and peptide analogs derived from saposin C. The active agent contained within the liposome may comprise biomolecules and/or organic molecules. This technology can be used for both cosmetic and medicinal applications in which the objective is delivery of the active agent within and/or beneath biological membranes or across the blood-brain barrier and neuronal membranes. | 01-26-2012 |
20120010234 | USE OF VEGF-D IN THE DIAGNOSIS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) DISEASE - Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided. | 01-12-2012 |
20120004427 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES - A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained. | 01-05-2012 |
20120004189 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 01-05-2012 |
20110312918 | METHOD FOR IDENTIFYING AGENTS FOR INHIBITING CELL MOTILITY AND INVASIVENESS - The present invention provides a novel mechanistic pathway and methods related to this pathway for the identification of compounds for the treatment of diseases involving cell proliferation, invasion and/or metastasis such as cancer. In particular, the instant invention relates to the phosphatase activity of Eya and the Eya-Six complex as a target for identifying novel therapeutic agents for the treatment of proliferative, invasive and/or metastatic disorders, and compositions identified using the methods disclosed herein. | 12-22-2011 |
20110301046 | Methods of Determining Efficacy of Glucocorticoid Treatment of Eosinophilic Esophagitis - The present invention concerns methods useful in diagnosing, identifying and monitoring the progression of eosinophilic esophagitis through measurements of gene products. | 12-08-2011 |
20110217715 | GENE EXPRESSION IN DUCHENNE MUSCULAR DYSTROPHY - Gene expression in peripheral blood from individuals with Duchenne muscular dystrophy (DMD), compared to control individuals, demonstrated differential gene sets that could be used in a method to diagnose DMD, to evaluate effect of DMD therapy, and/or to evaluate propensity to DMD. | 09-08-2011 |
20110212898 | CHIMERIC PEPTIDES FOR THE REGULATION OF GTPASES - Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene. | 09-01-2011 |
20110207659 | OLIGOSACCHARIDE COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF INFECTION - Oligosaccharides and oligosaccharides linked to backbones such as proteins, methods for making such oligosaccharides and methods for using them to treat and/or prevent various disorders are described. | 08-25-2011 |
20110200580 | METHODS OF TREATMENT AND PREVENTION OF DIET-INDUCED OBESITY AND SEQUELAE THEREOF - Disclosed are methods of treating or preventing diet-induced obesity and/or one or more sequelae thereof in a subject. These methods comprise administering to a subject in need of treatment or at risk for developing diet-induced obesity and/or one or more sequelae thereof, a therapeutically effective amount of a pharmaceutical composition comprising at least one inhibitor of RP 105 and/or MD-I activity. Also disclosed are methods of identifying compounds that inhibit development of diet-induced obesity and/or one or more sequelae thereof. In some aspects, these methods comprise: providing at least one first cell comprising TLR4, MD-2. RP105. MD-K and a TLR4-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with lipopolysaccharide and with a candidate compound; and determining a level of expression of the reporter in the presence of the LPS and the candidate compound, in some aspects, these methods comprise: providing at least one first cell comprising TLR2, TLR1, TLR6, MD-2, RP H/S, MD-K and a TLR2-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with a lipopeptide ligand of TLR2 and with a candidate compound, and determining a level of expression of the reporter in the presence of the lipopeptide ligand of TLR2 and the candidate compound | 08-18-2011 |
20110195500 | METHODS AND COMPOSITIONS FOR MITIGATING EOSINOPHILIC ESOPHAGITIS BY MODULATING LEVELS AND ACTIVITY OF EOTAXIN-3 - Eotaxin-3, as a marker for eosinophilic esophagitis and methods of assessing, mitigating, and monitoring eosinophilic esophagitis by altering eotaxin-3 and/or CCR3 function, are disclosed. | 08-11-2011 |
20110177996 | REGULATORY PROTEINS IN LUNG REPAIR AND TREATMENT OF LUNG DISEASE - The DNA-binding protein Sox17 has been found to play an important role in repair of pulmonary tissue after damage, disease, or injury. Nucleic acids encoding proteins involved in pulmonary repair, such as Sox17 and Spdef, can be used as a therapeutic composition for treating pulmonary disease. Methods of treatment of pulmonary injuries or pulmonary diseases are also disclosed, as are methods of identifying compounds effective in treating pulmonary injuries and diseases. | 07-21-2011 |
20110136153 | Use of VEGF-D in the Diagnosis of Lymphangioleiomyomatosis (LAM) Disease - Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided. | 06-09-2011 |
20110135651 | METHOD AND COMPOSITION FOR ENHANCING HEMATOPOIETIC STEM CELL MOBILIZATION - A therapeutic combination for improved mobilization of the hematopoietic stem and progenitor cells, and methods of use thereof are described. The therapeutic combination comprises G-CSF and an inhibitor of the EGFR signaling pathway. The role of EGFR is established by several lines of evidence, including use of quantitative trait locus analysis to map the chromosomal location of the non-G-CSF enhancement of hematopoietic stem and progenitor cells mobilization. Further, several different modes of inhibiting EGFR signaling all provide for an enhanced G-CSF induced mobilization of hematopoietic stem cells. | 06-09-2011 |
20110020274 | MOBILIZATION OF HEMATOPOIETIC STEM CELLS - Methods, processes, uses, and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells and/or cancer stem cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as a Cdc-42 specific inhibitor alone or in combination with one or more additional agents. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve specific inhibition of the Cdc42 GTPase to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject. | 01-27-2011 |
20110003844 | REGULATION OF CARDIAC CONTRACTILITY AND HEART FAILURE PROPENSITY - The methods and compositions of the present invention find use in altering expression of PKCα in transgenic animals. The compositions of the invention include isolated transgenic animal cells, transgenic tissue, transgenic animals, and transgenic mice. The transgenic animals of the invention exhibit altered PKCα activity. The methods allow generation of transgenic animals with altered expression of PKCα. The invention allows modulation of cardiac contractility. In particular, the invention provides a method for altering the susceptibility of a transgenic animal to cardiomyopathy. A transgenic animal of the invention finds use in identifying anti-cardiomyopathic compounds. | 01-06-2011 |
20100286053 | PLASMINOGEN ACTIVATOR INHIBITOR AMELIORATION OF NEWBORN HYPOXIC ISCHEMIC BRAIN INJURY - Plasminogen activators as potential therapeutic targets in neonatal hypoxia ischemia (HI) brain injury. Use of plasminogen activator inhibitor-1 (PAI-1) to ameliorate HI encephalopathy related disease. Use of PAI-1 as preventive treatment of cerebral palsy (CP). | 11-11-2010 |
20100267575 | GENE ARRAY TECHNIQUE FOR PREDICTING RESPONSE IN INFLAMMATORY BOWEL DISEASES - Disclosed are methods for classifying individuals having or suspected of having an inflammatory bowel disease, such as Crohn's Disease or Ulcerative Colitis, as “responders” or “non-responders” to first-line treatment, generally comprising the steps of a) obtaining, a biological sample from the individual, b) isolating mRNA from the biological sample c) determining a gene expression profile from the biological sample; and d) comparing the gene expression profile of the individual to a reference gene expression profile or other suitable control such that changes in expression can be used to stratify individuals and predict efficacy of first-line therapy. A gene expression system is further provided for carrying out these methods. | 10-21-2010 |
20100261774 | Methods for the modulation of Leishmania major infection in mammals - Embodiments of the invention include methods for treating an infection of a mammal by an organism, such as | 10-14-2010 |
20100172897 | Diagnosis and Prevention of Fetal Heart Disease - The present invention relates to a method for assessing the likelihood of the presence or formation of fetal heart disease (such as HLHS) in a fetus. In this methodology, the mother, either before or during pregnancy, is tested for the presence of anti-strep antibodies. If positive, the fetus is evaluated and monitored for the presence of fetal heart disease; the fetus can be treated, if appropriate. In addition, either prior to pregnancy or during the first trimester, the mother can be treated to prevent the formation of such antibodies or to neutralize their presence or effect fetal heart tissue. | 07-08-2010 |
20100120705 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 05-13-2010 |
20100038317 | HEMOFILTRATION SYSTEM AND METHOD BASED ON MONITORED PATIENT PARAMETERS, SUPERVISORY CONTROL OF HEMOFILTRATION, AND ADAPTIVE CONTROL OF PUMPS FOR HEMOFILTRATION - A multipurpose hemofiltration system and method are disclosed for the removal of fluid and/or soluble waste from the blood of a patient. The system continuously monitors the flow rates of drained fluid, blood, and infusate. When necessary, the pumping rates of the infusate, drained fluid and blood are adjusted to remove a preselected amount of fluid from the blood in a preselected time period. A supervisory controller can monitor patient parameters, such as heart rate and blood pressure, and adjust the pumping rates accordingly. The supervisory controller uses fuzzy logic to make expert decisions, based upon a set of supervisory rules, to control each pumping rate to achieve a desired flow rate and to respond to fault conditions. An adaptive controller corrects temporal variations in the flow rate based upon an adaptive law and a control law. | 02-18-2010 |
20090311663 | Organ Transplant Solutions and Method for Transplanting Organs - A preservation solution for organs waiting to be transplanted is disclosed; the method of using the solution in a transplantation procedure is also disclosed. The preservation solutions comprise a balanced isotonic aqueous solution comprising sodium, potassium, calcium, magnesium and bicarbonate ions in a physiologically acceptable amount, together with an effective amount of a mutein of the C5 | 12-17-2009 |
20090297496 | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases - The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome, | 12-03-2009 |
20090269373 | Saposin C-DOPS: A Novel Anti-Tumor Agent - Compositions and methods for treating subjects with disorders characterized by hyper-proliferating cells such as tumors and cancers are provided. The compositions comprise agents that are combinations of saposin C (or prosaposin-related polypeptides) and phospholips (or inner leaflet components). This anti-tumor agent is administered in the methods of the invention according to a dosing regimen. Administering an agent of the invention results in a positive therapeutic response in a subject with a tumor. | 10-29-2009 |
20090233275 | EOTAXIN-3 IN EOSINOPHILIC ESOPHAGITIS - Eotaxin-3, as a marker for eosinophilic esophagitis and methods of assessing, mitigating, and monitoring eosinophilic esophagitis by altering eotaxin-3 and/or CCR3 function, are disclosed. | 09-17-2009 |
20090203617 | CHIMERIC PEPTIDES FOR THE REGULATION OF GTPASES - Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene. | 08-13-2009 |
20090018185 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 01-15-2009 |
20080242615 | SURFACTANT PROTEIN-D FOR PREVENTION AND TREATMENT OF LUNG INFECTIONS AND SEPSIS - Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Administration of SP-D protein or fragments thereof is useful for the prevention or treatment of sepsis or lung infection. | 10-02-2008 |